. The mainstay of diagnosis is the cytological examination (Glass et al., 1979) of the cerebrospinal fluid (CSF) although in the last decade novel methods became available, i.e. detection of tumourmarkers ( van Zanten et al., 1988b ) and more recently immunohistochemical techniques (Coakham et al., 1984a,b; Goodson & Strauss, 1979; Hancock & Medley, 1983) . Monoclonal antibodies against specific antigens can detect (either qualitatively or, more often, quantitatively) malignant cells. One report (Boogerd et al., 1988) Since preliminary analysis did not demonstrate any differences between haematological malignancies and solid tumours, these tumour-groups will be considered together. had clinical signs and progression compatible with a diagnosis of neoplastic meningitis. Neurological signs included cranial nerve dysfunction, mental changes or multiple radicular deficits. Considering cytology the gold standard, the results as shown in Table I indicate that 13 out of 68 patients suffered from neoplastic meningitis. The sensitivity of immunohistochemistry then is 0.54 (7 positive on immunohistochemistry vs 13 positive on cytology) and its specificity is 0.98 (54 negative on immunohistochemistry vs 55 negative on cytology). However, the extra yield of immunohistochemical analysis in 68 patients is just one. Combining cytology and immunohistochemistry the gain is nearly 8%.
Spinal fluid protein and LDH levels did not influence the results on immunohistochemical analysis. The majority of positive cytologies (53.8%) were observed in patients with a cell count of less than 11 cells (Table II) . Even in the presence of a low cell count (<11 cells) immunohistochemical analysis is still feasible and can lead to positive results (37.5%).
Discussion
A diagnosis of MC or ML is usually made on clinical grounds and can be confirmed by radiological methods (CTscan, myelography) and, most importantly, CSF cytology (Olsen et al., 1974; Little et al., 1974; Glass et al., 1979) . When malignant cells, using standard cytological techniques, are found in the CSF of a patient with a previously undetected cancer, it is often unclear what type of malignancy is present. Under these circumstances, using a broad panel of monoclonal antibodies, immunohistochemistry has been proven to be very helpful in determining the nature of the tumour (Coakham et al., 1984a,b) . However, when the patient is known with cancer and cytology is negative, it is uncertain whether immunohistochemistry is more sensitive than cytology to detect cancer cells. Boogerd et al. (1988) analysed this question in 118 samples of CSF, largely obtained by a ventricular tap via an Ommaya Our results were obtained in a larger series but confirm their observations. Our CSF-samples showed in 90% similar results on both cytology and immunohistochemistry. Only one patient had positive immunohistochemistry and a negative cytology and in this patient the cell count was high. We conclude that immunohistochemistry should not be used as a screening test for leptomeningeal disease in patients with cancer. Only when CSF cytology fails in patients with a strong suspicion of carcinomatous or lymphomatous leptomeningitis, may immunohistochemistry be helpful.
